Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 05 2023
20 05 2023
Historique:
medline:
19
5
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M. A total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed. IPSS-M improved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance was 0.81 IPSS-M improves MDS prognostication and might result in a more effective selection of candidates to HSCT. Additional factors other than gene mutations can be involved in determining HMA sensitivity. The definition of a minimum set of relevant genes may facilitate the clinical implementation of the score.
Identifiants
pubmed: 36930857
doi: 10.1200/JCO.22.01784
pmc: PMC10414702
doi:
Banques de données
ClinicalTrials.gov
['NCT04889729']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2827-2842Références
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Nat Genet. 2017 Mar;49(3):332-340
pubmed: 28092685
Leukemia. 2017 Nov;31(11):2449-2457
pubmed: 28321120
J Clin Oncol. 2021 Apr 10;39(11):1223-1233
pubmed: 33539200
Leukemia. 2015 Jul;29(7):1502-13
pubmed: 25721895
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811-6
pubmed: 19805378
Leukemia. 2016 Mar;30(3):649-57
pubmed: 26464171
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Biometrics. 2008 Mar;64(1):172-9
pubmed: 17680835
Blood. 2004 Jul 15;104(2):579-85
pubmed: 15039286
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
N Engl J Med. 2022 May 26;386(21):1998-2010
pubmed: 35613022
Blood. 2013 Dec 12;122(25):4021-34
pubmed: 24136165
J Clin Oncol. 2021 Nov 20;39(33):3737-3746
pubmed: 34406850
Blood. 2013 Oct 24;122(17):2943-64
pubmed: 23980065
Blood. 2017 Mar 30;129(13):1753-1762
pubmed: 28096091
J Clin Oncol. 2017 Jul 1;35(19):2157-2164
pubmed: 28463633
Nat Commun. 2015 Jan 09;6:5901
pubmed: 25574665
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Oncotarget. 2018 Jun 12;9(45):27882-27894
pubmed: 29963245
J Clin Oncol. 2016 Oct 20;34(30):3627-3637
pubmed: 27601546